Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2019 September;44(3) > Minerva Endocrinologica 2019 September;44(3):259-63

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   

Minerva Endocrinologica 2019 September;44(3):259-63

DOI: 10.23736/S0391-1977.17.02773-0

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Study on regulation of adipokines on body fat distribution and its correlation with metabolic syndrome in type 2 diabetes mellitus

Xiaoxi LIU 1, Xiaojuan LI 2, Changhui LI 2, Chengjun GONG 2, Songyan LIU 2, Yan SHI 3

1 Department of Endocrine Rehabilitation, the First Affiliated Hospital of Xiamen University, Xiamen, China; 2 Department of Endocrine Rehabilitation, the First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China; 3 Liaoning University of Traditional Chinese Medicine, Shenyang, China


PDF


BACKGROUND: This paper aimed to investigate the regulating role of adipokine expression level in body fat distribution of patients with type 2 diabetes mellitus (T2MD) as well as its correlation with metabolic syndrome (MS).
METHODS: One hundred forty patients with T2MD admitted in the Endocrinology Department of the First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine from January 2017 to July 2017 were selected; their body height and weight were measured to calculate Body Mass Index (BMI); patients with a BMI ≤23.9 kg/m2 were included into control group (N.=49), and those with a BMI ≥24 kg/m2 into observation group (N.=91). Based on whether the patients were complicated with MS, they were divided into non-metabolic syndrome (N-MS) group (N.=79) and MS group (N.=61); the levels of serum dipeptidyl peptidase-4 (DPP-4), adiponectin (ADPN) and leptin as well as the contents of body fat and lean tissue of the two groups of patients were measured.
RESULTS: The serum DPP-4 level in observation group was remarkably elevated compared with that in control group (P<0.05), but there were no significant differences in the leptin and ADPN levels between the two groups (P>0.05). The serum DPP-4 and leptin levels were positively correlated with the total body fat mass (FAT) of the patients in observation group (r=0.461, P=0.004; r=0.433, P=0.007); DPP-4 level had a positive correlation with trunk fat mass (TRUNK F) (r=0.545, P=0.001) and limb fat mass (LIMB F) (r=0.412, P=0.005); the leptin level was positively correlated with LIMB F (r=0.513, P=0.001); the leptin and ADPN levels were negatively correlated with the content of lean tissue (r=-0.476, P=0.001; r=-0.344, P=0.021). Compared with those in N-MS group, the levels of serum DPP-4 and leptin were increased significantly, while the ADPN level was decreased notably (P<0.05) in MS group.
CONCLUSIONS: The adipokines DPP-4 and leptin in the serum can influence the body fat distribution of patients with T2MD; there is an important association of DPP-4, leptin and ADPN levels with MS, which may be used as therapeutic targets for multiple metabolism disorders of T2MD.


KEY WORDS: Dipeptidyl peptidase 4; Leptin; Adiponectin; Body fat distribution; Diabetes mellitus, type 2

top of page